Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

NCT05467748 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT05467748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05467748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Lead sponsor
VA Office of Research and Development
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 8, 2025
Completion date
December 7, 2029
Enrollment
66 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer